Abstract
Shortly after the cystic fibrosis (CF) gene was identified in 1989, the race began to develop a gene therapy for this condition. Major efforts utilized full-length cystic fibrosis transmembrane conductance regulator packaged into adenovirus, adeno-associated virus (AAV), or liposomes and delivered to the airways. The drive to find a treatment for CF based on gene therapy drove the early stages of gene therapy in general, particularly those involving AAV gene therapy. Since general overviews of CF gene therapy have already been published, this review considers specifically the efforts using AAV and is focused on honoring the contributions of Dr. Barrie Carter.
Original language | English (US) |
---|---|
Pages (from-to) | 538-541 |
Number of pages | 4 |
Journal | Human gene therapy |
Volume | 31 |
Issue number | 9-10 |
DOIs | |
State | Published - May 2020 |
Keywords
- Adeno-associated virus
- Clinical trials
- Cystic fibrosis
- Gene therapy
- Preclinical testing
ASJC Scopus subject areas
- Molecular Medicine
- Molecular Biology
- Genetics